[1]
“Preventive Strategies and Infectious Outcomes in Ruxolitinib-Treated Myeloproliferative Neoplasms”, Mediterr J Hematol Infect Dis, vol. 18, no. 1, Apr. 2026, doi: 10.4084/MJHID.2026.044.